Elusys Therapeutics, Inc.
about us technology product pipeline news&events careers
Elusys Overview Leadership Biodefense Corporate Fact Sheet
Executive Team Board of  Directors Scientific Advisory Board
Technology Heteropolymer Antibodies CR1 Vaccines Publications
Overview Process Animation
Antibody Heteropolymers Antigen Heteropolymers Anthrax Antibody
Pipeline Anthim Anthrax Antibody Staph A HP - ETI-211 Candida HP CR1 Vaccines
Press Releases Presentations
Our Values Working at Elusys Open Positions Benefits Location

NEWS & EVENTS

PRESS RELEASES 2005

2007   2006   2005   2004

 

December 17th, 2005

 

Elusys Presents Data on Therapeutic for Staphylococcus Aureus at iCAAC

 

October 19th, 2005

 

 

Elusys Therapeutics’ President, Elizabeth Posillico PH.D, Assumes Responsibilities of CEO and Director

 

October 3rd, 2005



Elusys Therapeutics’ Fast-Tracked Anthrax Drug, Anthim™ Advances into Human Clinical Trials

 

August 3rd, 2005

Elusys Awarded an Additional $5.4 Million from the U.S. Government for Continued Development of Anthim™

 

April 13th, 2005

 

Elusys to Present at Biosquare Conference in France

February 26th, 2005

Elusys Submits IND to Initiate Human Studies of Anthrax Drug

 

January 31st, 2005

 

Elizabeth Posillico Named President of Elusys

 

 

 

 

 

 

 

 

  • Copyright© 2008 Elusys Therapeutics, Inc. All Rights Reserved.
  • contact us
  • site map
  • careers